FKBP2DRUG
Development of FKBP51-Inhibitors to treat stress-related disorders: assessment of feasibility
| Coordinatore | MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 150˙000 € |
| EC contributo | 150˙000 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2013-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-09-01 - 2015-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | hostInstitution | 150˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The FK506-binding protein 51 (FKBP51) plays an important role in the human stress response. In research funded by my ERC Starting Grant I identified the molecular mechanisms of how a de-repressed FKBP51 mediates stress- and trauma-induced risk for psychiatric disorders in genetically vulnerable individuals, thus validating FKBP51 as a potential drug target for stress-related disorders. The current proof-of-concept proposal aims at providing a due diligence analysis to support the concept that the development of FKBP51-directed drugs is technically feasible and economically warranted.'